利拉鲁肽治疗对初发2型糖尿病伴肥胖患者代谢紊乱的调节作用

Regulatory Effect of Liraglutide on Metabolic Disorders in Patients with Newly Diagnosed Type 2 Diabetes Mellitus with Obesity

目的探析利拉鲁肽治疗对初发2型糖尿病伴肥胖患者代谢紊乱的调节作用。方法以2016年8月—2018年4月该院接收的108例初发2型糖尿病伴肥胖患者为例,随机分成对照组(54例)及研究组(54例),对照组采用二甲双胍治疗,研究组采用利拉鲁肽治疗,比较两组的临床疗效。结果研究组糖脂代谢指标与对照组相比明显更低(P<0.05);HDL-C(1.28±0.18)mmol/L,与对照组相比更高(P<0.05)。结论采用利拉鲁肽对初发2型糖尿病伴肥胖患者进行治疗可以有效改善其糖脂代谢水平,降低炎症反应。

Objective To investigate the regulation of liraglutide in the treatment of metabolic disorders in patients with type 2 diabetes mellitus and obesity. Methods A total of 108 patients with type 2 diabetes mellitus and obesity who were admitted to the hospital from August 2016 to April 2018 were randomly divided into the control group （54 cases） and the study group （54 cases）. The control group was treated with metformin. The study group treated with liraglutide and compared the clinical efficacy of the two groups. Results The glucose and lipid metabolism index of the study group was significantly lower than that of the control group （P〈0.05）; HDL-C （1.28±0.18） mmol/L was higher than the control group （P〈0.05）. Conclusion The use of liraglutide in the treatment of patients with early-onset type 2 diabetes with obesity can effectively improve the level of glucose and lipid metabolism and reduce the inflammatory response.